CLINICAL TRIALS PROFILE FOR FLOXURIDINE
✉ Email this page to a colleague
All Clinical Trials for Floxuridine
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00001576 ↗ | A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver | Completed | National Cancer Institute (NCI) | Phase 1 | 1997-07-01 | Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan. Postoperatively, patients will be treated with hepatic arterial infusion of floxuridine (FUDR), 0.2 mg/kg/day and leucovorin (LV), 15 mg/M2/day as a 2-week continuous infusion regimen. Hepatic and systemic toxicity, response to treatment, duration of response, and survival will be followed. |
NCT00002716 ↗ | Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 1996-01-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective for metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of intrahepatic floxuridine, leucovorin, and dexamethasone with that of systemic fluorouracil and leucovorin in treating patients who have unresectable liver metastases from colorectal cancer. |
NCT00002716 ↗ | Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Completed | Alliance for Clinical Trials in Oncology | Phase 3 | 1996-01-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective for metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of intrahepatic floxuridine, leucovorin, and dexamethasone with that of systemic fluorouracil and leucovorin in treating patients who have unresectable liver metastases from colorectal cancer. |
NCT00002783 ↗ | Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1996-05-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy before and after surgery in treating patients with high-risk stomach cancer. |
NCT00002783 ↗ | Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | 1996-05-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy before and after surgery in treating patients with high-risk stomach cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Floxuridine
Condition Name
Clinical Trial Locations for Floxuridine
Trials by Country
Clinical Trial Progress for Floxuridine
Clinical Trial Phase
Clinical Trial Sponsors for Floxuridine
Sponsor Name